

**Immunization Program  
Vaccines for Children Program  
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Summary  
January 2011**

The purpose of this vaccine summary is to:

1. Provide revised recommendations for the use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccines, MMWR, January 14, 2011 / 60(01);13-15.
2. Provide revised Iowa VFC Program recommendations for the use of Tdap effective January 14, 2011.

**Food and Drug Administration (FDA)**

**Adacel** manufactured by sanofi pasteur

- o 2005 - Indicated for persons 11-64 years of age

**Boostrix** manufactured by GlaxoSmithKline

- o 2005 - Indicated for persons 10-18 years of age
- o 2008 - Indicated for persons 10-64 years of age

**Advisory Committee on Immunization Practices (ACIP)** – *Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on Immunization Practices, 2010, published January 14, 2011 / 60(01);13-15.*

**VFC Resolution** – the VFC Program follows the ACIP recommendations for the use of Tdap vaccine for VFC eligible children through 18 years of age.

**ACIP Recommended Schedule for Tdap Vaccine**

- o Adults age 65 years and older
  - Those who have or anticipate having close contact with an infant less than 12 months of age should receive a single dose of Tdap.
  - Other adults 65 years of age and older may be given a single dose of Tdap.
- o Tdap is indicated for a single booster dose at 11 or 12 years of age if the childhood DTP/DTaP vaccination series has been completed.
- o Tdap should be given to persons 7-10 years of age and older who have received fewer than 5 doses of DTP/DTaP or 4 doses of DTP/DTaP if the fourth dose was administered at age 4 years or older; or have never been vaccinated against tetanus, diphtheria, or pertussis.
- o Adolescents and adults who have not received Tdap should receive a single dose of Tdap in place of a single Td booster dose.
- o Tdap is recommended only for a single dose across all age groups.
- o Tdap can be administered regardless of the interval since the last tetanus or diphtheria containing vaccine.

**Recommended Dosage**

Single 0.5 mL intramuscular. Refer to package insert for additional information.

**Vaccine Storage and Handling**

- o Store refrigerated at 2 - 8° C, 35 - 46° F
- o Do not freeze

### **Precautions and Contraindications**

#### **Precautions**

Because individuals that receive vaccinations may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after administration is recommended. Refer to package insert for additional precaution information.

#### **Contraindications**

Tdap vaccine is contraindicated for persons with a history of immediate hypersensitivity to any vaccine component. Refer to package insert for additional contraindication information.

### **Vaccine Licensure / VFC Implementation**

The ACIP is a federal advisory committee whose role is to provide advice and guidance regarding the most appropriate application of vaccines for effective vaccine preventable disease control. The FDA is responsible for the licensure of vaccines. Upon FDA approval the ACIP convenes and makes decisions on vaccine recommendations. A VFC resolution vote is required for the inclusion of new vaccines into the VFC Program or the modification of existing resolutions. The Centers for Disease Control and Prevention (CDC) then negotiates a contract for the purchase of vaccines. This contract is normally finalized within three months. VFC vaccine must be administered according to the guidelines outlined by the ACIP recommendations and VFC resolutions.

CDC allocates individual state VFC funding based upon eligible populations, anticipated vaccine uptake and negotiated federal contract amounts. CDC establishes monthly vaccine allocations for each vaccine. Additional 317 CDC discretionary funds are used to vaccinate underinsured individuals seen at Local Public Health Agencies (LPHAs) who are not eligible under VFC guidelines. Each state determines the vaccine implementation date that is based upon the above process, which is generally four to six months following vaccine licensure.

### **School Requirements**

The role of school laws is to assist in the removal of barriers to vaccine and to prevent the transmission of disease in school settings. Tdap vaccine is not required for school enrollment.

### **IDPH/Immunization Program Recommendations**

The IDPH, Immunization Program routinely follows and promotes the ACIP Recommended Immunization schedule. The Immunization Program is implementing Meningococcal vaccine in accordance with the ACIP recommendations and the VFC resolution.

The complete MMWR article entitled *Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine from the Advisory Committee on Immunization Practices, 2010, published January 14, 2011 / 60(01);13-15* can be found at the following link:

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s\\_cid=mm6001a4\\_e%0d%0a](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s_cid=mm6001a4_e%0d%0a)

Tdap CPT Code 90715